VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $109,166.43 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 6,533 shares of the stock in a transaction dated Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43. Following the sale, the insider directly owned 3,552,710 shares in the company, valued at approximately $59,365,784.10. The trade was a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total value of $45,908.30.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Down 1.0%

NASDAQ BBH opened at $204.23 on Friday. The stock has a 50-day moving average of $193.07 and a 200 day moving average of $191.95. VanEck Biotech ETF has a twelve month low of $154.75 and a twelve month high of $212.54.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Segall Bryant & Hamill LLC acquired a new stake in VanEck Biotech ETF in the 1st quarter valued at $881,000. Paragon Private Wealth Management LLC raised its position in VanEck Biotech ETF by 5.3% during the first quarter. Paragon Private Wealth Management LLC now owns 15,368 shares of the company’s stock worth $2,890,000 after acquiring an additional 775 shares during the period. Bank of America Corp DE raised its position in VanEck Biotech ETF by 44.3% during the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after acquiring an additional 20,375 shares during the period. Royal Bank of Canada lifted its holdings in VanEck Biotech ETF by 4.3% during the first quarter. Royal Bank of Canada now owns 13,843 shares of the company’s stock valued at $2,603,000 after purchasing an additional 565 shares in the last quarter. Finally, Wealthfront Advisers LLC lifted its holdings in VanEck Biotech ETF by 27.0% during the first quarter. Wealthfront Advisers LLC now owns 7,004 shares of the company’s stock valued at $1,317,000 after purchasing an additional 1,491 shares in the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.